ubiquitinproteasom
system
up
primari
mechan
intracellular
protein
transcript
factor
mani
proteotox
protein
aggregationpron
structur
degrad
up
reportedli
downregul
variou
neurodegen
disord
increas
proteasom
activ
shown
benefici
mani
relat
diseas
model
proteasom
function
tonic
inhibitori
condit
possibl
via
ubiquitin
chaintrim
function
proteasomeassoci
deubiquitin
enzym
dub
identifi
three
specif
rna
aptam
inhibit
deubiquitin
activ
nucleotid
sequenc
noncytotox
aptam
contain
conserv
ggagg
motif
grich
region
upstream
similar
secondari
structur
effici
elev
proteasom
activ
determin
increas
degrad
small
fluorogen
peptid
substrat
physiolog
polyubiquitin
protein
addit
proteasom
degrad
tau
protein
facilit
presenc
aptam
vitro
result
indic
novel
inhibitori
aptam
use
enhanc
proteasom
activ
facilit
degrad
proteotox
protein
therebi
protect
cell
variou
neurodegen
stressor
proteasom
primari
proteolyt
machineri
use
cell
homeostasi
variou
regulatori
protein
catabol
process
mainli
mediat
ubiquitin
ub
depend
proteolysi
protein
intrins
disord
protein
degrad
proteasom
ubindepend
manner
proteasom
multimer
complex
compos
core
particl
cp
complex
regulatori
particl
rp
complex
rp
recogn
polyubiquitin
polyub
chain
substrat
deubiquitin
proteasom
proteolysi
initi
transloc
substrat
catalyt
caviti
cp
ubiquitinproteasom
system
up
appear
qualiti
control
mechan
one
accomplish
proteasomeassoci
deubiquitin
enzym
dub
interact
bind
locat
rp
rel
far
substrat
entri
pore
ub
receptor
thought
mediat
stepwis
disassembl
ub
chain
distal
end
chaintrim
effect
delay
proteasom
degrad
weaken
interact
ub
receptor
proteasom
polyub
chain
substrat
delet
gene
chemic
treatment
inhibitor
result
acceler
proteasom
degrad
variou
target
substrat
find
suggest
potenti
therapeut
target
treat
diseas
toxic
protein
accumul
howev
also
report
trim
ub
chain
might
promot
proteasom
degrad
mechan
regul
remain
elucid
probabl
involv
rate
ub
chaintrim
proteasom
coordin
substrat
transloc
aptam
molecul
compos
singlestrand
nucleic
acid
base
gener
vitro
select
process
larg
pool
random
sequenc
techniqu
known
system
evolut
ligand
exponenti
enrich
selex
sinc
introduct
selex
technolog
wide
rang
biolog
target
includ
small
molecul
peptid
protein
nucleic
acid
cell
tissu
organ
report
bind
aptam
high
specif
aptam
often
refer
chemic
antibodi
one
class
biomolecul
manufactur
bind
multipl
differ
target
rna
aptam
isol
shown
stabl
conform
vivo
follow
modif
specif
bind
protein
human
immunodefici
viru
tat
revers
transcriptas
hepat
c
viru
proteasehelicas
rnadepend
rna
polymeras
sever
acut
respiratori
syndrom
ntpasehelicas
addit
rna
aptam
bind
prostat
cancer
cell
extracellular
portion
prostatespecif
membran
antigen
brain
tissu
aptam
bind
specif
protein
repress
enzymat
activ
protein
proteinprotein
interact
activ
site
interact
motif
usual
offer
expos
heteroatom
mediat
hydrogen
bond
strong
interact
aptam
therapeut
applic
inhibitori
aptam
often
chemic
modifi
resist
degrad
mediat
serum
agerel
macular
degener
drug
pegaptanib
aptam
target
vascular
endotheli
growth
factor
conjug
kda
polyethylen
glycol
contain
invert
nucleotid
terminu
consid
rapid
progress
aptam
biolog
relat
technolog
aptam
consid
essenti
understand
modul
variou
pathophysiolog
process
overcom
limit
smallmolecul
inhibitor
identifi
three
novel
rna
aptam
suppress
deubiquitin
activ
vitro
consist
effect
upon
proteasom
aptam
enhanc
proteasom
activ
facilit
degrad
alzheim
diseas
ad
implic
tau
protein
inhibitori
aptam
noncytotox
effect
reliev
proteopath
stress
cultur
cell
therefor
aptam
could
offer
interest
altern
delay
aggreg
process
toxic
aggregationpron
protein
purif
recombin
protein
transform
escherichia
coli
strain
purifi
glutathion
stransferas
gst
conjug
counterpart
respect
use
previous
describ
method
modif
cultur
incub
optic
densiti
nm
od
ad
iptg
cultur
final
concentr
mm
allow
cultur
incub
overnight
cell
harvest
phosphatebuff
salin
pb
contain
proteas
inhibitor
cocktail
lyse
sonic
follow
centrifug
lysat
filter
supernat
incub
gst
sepharos
resin
ge
healthcar
littl
chalfont
uk
h
wash
pb
elut
use
mm
reduc
glutathion
mm
trishcl
ph
gst
tag
remov
incub
protein
fraction
thrombin
cleavag
buffer
mm
trishcl
ph
mm
nacl
mm
cacl
vv
h
room
temperatur
rt
centrifug
supernat
incub
benzamidin
sepharos
resin
ge
healthcar
remov
residu
thrombin
purifi
gst
data
shown
separ
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
gel
stain
coomassi
brilliant
blue
cbb
determin
size
puriti
protein
fig
vitro
select
rna
aptam
random
rna
librari
gener
previous
describ
use
polymeras
chain
reaction
pcr
vitro
transcript
dna
templat
bp
contain
random
nucleotid
briefli
aptam
librari
templat
dna
ggg
ttc
act
gca
gac
ttg
acg
aag
ctt
na
atg
gat
cca
cat
cat
cta
cga
att
gener
pcr
use
forward
primer
gat
aat
acg
act
cac
tat
agg
gtt
cac
tgc
aga
ctt
gac
contain
promot
sequenc
underlin
revers
primer
tta
cct
agg
tgt
aga
tgc
tta
fig
rna
aptam
librari
prepar
use
rna
polymeras
vitro
transcript
buffer
mm
trishcl
ph
mm
mgcl
mm
spermidin
mm
dtt
mm
ntp
h
product
treat
dnase
thermo
scientif
min
subject
denatur
urea
page
use
purifi
gel
g
aliquot
gener
rna
pool
incub
l
gst
sepharos
resin
bind
buffer
mm
trishcl
ph
mm
nacl
mm
mgcl
mm
dtt
wv
bovin
serum
albumin
bsa
min
rt
occasion
shake
rnabead
complex
transfer
porou
centrifug
column
pierc
rna
pool
unbound
sepharos
resin
collect
centrifug
procedur
perform
use
g
gst
protein
remov
rna
nonspecif
bound
gst
glutathion
resin
round
select
gsttag
protein
incub
g
preclear
rna
pool
l
bind
buffer
min
rt
l
gst
sepharos
resin
addit
min
rt
quantiti
gsttag
protein
gradual
decreas
g
round
g
round
g
round
g
round
g
round
achiev
stringent
condit
complex
wash
three
time
pb
elut
mm
glutathion
bind
buffer
elut
rna
purifi
phenol
chloroform
extract
ethanol
precipit
reversetranscrib
accupow
rt
premix
bioneer
amplifi
pcr
amplifi
cdna
purifi
use
accuprep
gel
purif
kit
bioneer
transcrib
rna
polymeras
next
round
select
fig
complex
dissoci
elut
buffer
contain
excess
imidazol
rna
bound
prepar
phenol
chloroform
extract
ethanol
precipit
recov
rna
revers
transcrib
amplifi
polymeras
chain
reaction
pcr
vitro
transcrib
follow
round
select
result
cdna
amplifi
clone
pcdna
human
proteasom
ptsm
purifi
cell
line
proteasom
treat
ubiquitinvinylmethylest
ubvm
yield
vmeptsm
ptsm
g
vmeptsm
g
separ
gradient
gel
stain
cbb
e
western
blot
analysi
proteasom
subunit
approxim
ng
ptsm
vmeptsm
subject
sdspage
crop
gelsblot
use
e
clone
sequenc
round
select
result
cdna
pcramplifi
use
forward
gat
aat
acg
act
cac
tat
agg
gtt
cac
tgc
aga
ctt
gac
revers
tta
cct
agg
tgt
aga
tgc
tta
primer
amplicon
digest
hindiii
ecori
clone
pcdna
vector
invitrogen
sequenc
secondari
structur
select
rna
aptam
predict
mfold
program
base
zuker
algorithm
http
mfold
rnaalbanyedu
subsequ
activ
test
inhibit
assay
individu
rna
aptam
amplifi
pcr
use
forward
att
aat
acg
act
cac
tat
agg
revers
tta
cct
agg
tgt
aga
tgc
tta
primer
vitro
transcrib
use
rna
polymeras
use
sequenc
irrelev
aptam
control
uuu
guc
uag
cgc
gua
gug
ggg
aga
ugu
ugu
gau
acu
ggg
g
measur
rna
aptam
bind
load
immobil
pmol
gst
onto
gst
sepharos
resin
ad
pmol
rna
aptam
rna
elut
resin
reversetranscrib
result
cdna
subject
pcr
agaros
gel
electrophoresi
follow
ethidium
bromid
stain
carri
visual
proteinbound
rna
wv
agaros
gel
clone
use
primer
mutant
gca
gtg
atg
tgc
ttc
taa
aaa
aca
acc
taa
aaa
aat
tgc
mutant
ctg
aaa
aaa
agt
tag
ttt
cgc
tgg
ttt
aaa
atc
ggt
gcg
mutant
aaa
aaa
aag
gct
cgt
ttg
gcc
tgc
cga
aaa
aag
gcc
ggg
aptam
mutant
gener
insert
correspond
oligonucleotid
pcdna
vector
amplifi
pcr
use
forward
revers
primer
vitro
transcrib
use
rna
polymeras
describ
human
proteasom
purifi
affin
chromatographi
stabl
cell
line
harbor
biotintag
human
previous
describ
modif
cell
cultur
dish
harvest
lysi
buffer
mm
nah
po
ph
mm
nacl
glycerol
mm
mgcl
mm
atp
mm
dtt
contain
proteas
inhibitor
homogen
use
dounc
homogen
centrifug
supernat
incub
streptavidin
agaros
resin
millipor
h
bead
wash
lysi
buffer
tev
buffer
mm
trishcl
ph
mm
atp
glycerol
proteasom
elut
resin
incub
tev
proteas
invitrogen
tev
buffer
h
concentr
use
amicon
ultraspin
column
millipor
inhibit
deubiquitin
activ
proteasom
ubiquitinvinylmethylest
ubvm
lifesensor
ad
previous
describ
residu
ubvm
remov
wash
bead
three
time
bed
volum
wash
buffer
proteasom
ng
separ
sdspage
use
gradient
gel
gel
stain
use
ezway
silver
stain
kit
koma
biotech
cbb
obtain
proteasom
design
vmeproteasom
test
confirm
elimin
deubiquitin
activ
use
ubrhodamin
hydrolysi
assay
lifesensor
data
shown
bind
proteasom
effect
aptam
interact
proteasom
investig
use
proteasom
affin
pulldown
assay
cell
harvest
lysi
buffer
cell
lysat
homogen
use
ml
syring
needl
centrifug
supernat
incub
rna
aptam
min
streptavidin
agaros
resin
millipor
h
bead
wash
lysi
buffer
boil
sd
sampl
buffer
bind
proteasom
monitor
western
blot
use
antibodi
bethyl
laboratori
inc
base
hydrolysi
fluorogen
sucllvyamc
peptid
chymotrypsinlik
activ
proteasom
measur
determin
proteolyt
activ
sucllvyamc
hydrolysi
assay
carri
use
purifi
proteasom
sucllvyamc
enzo
life
scienc
assay
buffer
mm
trishcl
ph
mm
edta
mgml
bsa
mm
atp
mm
dtt
hydrolysi
reaction
carri
use
proteasom
activ
vmeproteasom
along
nm
nm
presenc
absenc
gml
equival
nm
rna
aptam
rna
aptam
incub
proteasom
min
ad
substrat
examin
effect
rna
aptam
rna
aptam
incub
min
vmeproteasom
min
ad
substrat
kindli
provid
eunic
eunkyeong
kim
provid
kyeong
kyu
kim
proteasom
activ
deubiquitin
activ
monitor
measur
free
amc
fluoresc
respect
black
plate
use
tecan
infinit
fluoromet
hydrolysi
activ
aptam
monitor
concentr
cours
normal
fluoresc
intens
concentr
rhodamin
achiev
use
free
rhodamin
standard
curv
santa
cruz
biotechnolog
k
k
cat
paramet
determin
scientif
report
doi
nonlinear
regress
fit
model
deriv
michaelismenten
equat
use
graphpad
prism
graphpad
inc
usa
ubiquitin
recombin
tau
polyubiquitin
py
motif
prepar
previous
describ
modif
ub
conjug
reaction
conduct
incub
pmol
py
pmol
pmol
pmol
nmol
ub
buffer
mm
trishcl
ph
mm
nacl
mm
dtt
mm
atp
mm
mgcl
h
conjug
absorb
ninta
resin
qiagen
germani
wash
buffer
mm
trishcl
ph
mm
nacl
glycerol
elut
mm
imidazol
wash
buffer
dialyz
wash
buffer
contain
glycerol
recombin
tau
chip
protein
express
purifi
vector
use
convent
purif
method
unphosphoryl
tau
g
incub
ng
g
g
chip
g
g
ub
h
rt
l
reaction
vitro
degrad
assay
purifi
human
proteasom
nm
incub
nm
ubtau
proteasom
assay
buffer
mm
trishcl
ph
mm
nacl
glycerol
mm
atp
mm
mgcl
mm
dtt
certain
instanc
incub
proteasom
min
reaction
initi
examin
effect
rna
aptam
vitro
degrad
assay
aptam
incub
min
ad
proteasom
reaction
termin
ad
sdspage
sampl
buffer
subject
sdspage
ubtau
degrad
monitor
immunoblot
use
antibodi
millipor
tau
clone
invitrogen
respect
cell
cultur
rna
aptam
transfect
cell
studi
cultur
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
aptam
transfect
perform
plate
use
lipofectamin
invitrogen
cell
transfect
h
whole
cell
extract
collect
h
media
chang
assess
cell
viabil
cell
viabil
assess
use
modifi
bromid
mtt
assay
hela
cell
cultur
approxim
confluent
plate
treat
control
aptam
complex
lipofectamin
variou
concentr
gml
h
ad
l
mtt
solut
well
incub
plate
co
h
media
discard
l
dimethyl
sulfoxid
ad
well
plate
incub
min
rt
absorb
solut
nm
determin
triplic
well
assay
condit
cell
surviv
also
assess
tau
induc
dox
oxid
stress
induc
paraquat
induc
tau
cell
line
incub
dox
pgml
paraquat
mm
h
transfect
aptam
tau
degrad
assay
induc
tau
cell
line
transfect
aptam
treat
variou
concentr
dox
h
wholecel
lysat
prepar
ripa
buffer
use
immunoblot
necessari
cell
treat
gml
cycloheximid
chx
enzo
life
scienc
harvest
sdspage
lane
load
extract
equal
cell
number
gener
correspond
glane
sampl
recov
one
well
plate
prepar
recombin
protein
select
rna
aptam
previous
show
yeast
mammalian
proteasomeassoci
dub
enzym
function
endogen
inhibitor
proteasom
ub
chaintrim
effect
might
antagon
degrad
mani
proteasom
substrat
small
molecul
inhibitor
facilit
proteolysi
howev
small
molecul
inhibitor
exhibit
rel
high
cytotox
low
inhibitori
efficaci
identifi
aptam
use
selex
techniqu
kda
kda
also
express
purifi
subsequ
analysi
aptam
proteasom
fig
select
rna
aptam
high
affin
specif
gener
pool
rna
approxim
molecul
contain
nt
random
core
sequenc
flank
promot
site
end
primerbind
site
end
fig
prior
initi
screen
perform
neg
select
round
remov
nonspecif
rna
bound
glutathionesepharos
resin
gst
protein
rna
pool
fig
stringenc
rna
bind
protein
increas
round
progress
see
method
human
proteasom
purifi
cell
line
stabli
express
polyhistidineand
biotintag
subunit
purifi
proteasom
show
approxim
molar
ratio
rp
cp
complex
fig
basal
deubiquitin
activ
strongli
activ
proteasom
although
subunit
respons
activ
remain
elucid
major
proteasom
deubiquitin
activ
irrevers
block
use
ubvm
form
adduct
cy
activ
site
thiol
proteas
dub
result
vmeproteasom
appear
retain
compon
normal
proteasom
fig
larg
amount
copurifi
rp
proteasom
fig
coval
modifi
ubvm
electrophoret
mobil
reduc
kda
correspond
size
ub
fig
indic
dub
enzym
proteasom
includ
fulli
inactiv
identif
aptam
inhibitori
effect
deubiquitin
activ
examin
rna
sequenc
randomli
select
clone
identifi
three
differ
aptam
rna
aptam
design
repres
respect
identifi
aptam
fig
aptam
contain
conserv
sequenc
similar
structur
motif
predict
mfold
addit
two
stemloop
secondari
structur
fig
sequenc
five
conserv
nucleotid
prior
activ
vmeptsm
nm
variou
concentr
protein
preincub
rna
aptam
gml
control
gml
random
rna
pool
use
note
alon
without
activ
proteasom
show
basal
ubrho
hydrolysi
activ
e
hydrolysi
variou
deubiquitin
enzym
dub
presenc
absenc
aptam
gml
f
hydrolysi
except
variou
concentr
incub
nm
nm
vmeptsm
nm
g
deubiquitin
activ
monitor
nm
hydrolysi
presenc
ptsm
gml
aptam
origin
rna
aptam
librari
random
rna
pool
use
control
data
repres
mean
sd
three
independ
experi
p
oneway
analysi
varianc
anova
bonferroni
multipl
comparison
test
rfu
rel
fluoresc
unit
ptsm
human
proteasom
vmeptsm
ubvmetr
human
proteasom
ggagg
follow
grich
sequenc
result
suggest
expos
ggagg
grich
sequenc
rna
aptam
could
import
interact
none
rna
aptam
found
bind
gsttag
protein
bind
assay
similar
selex
strategi
fig
howev
exhibit
high
affin
control
rna
aptam
bind
fig
mutat
consensu
ggagg
grich
sequenc
rna
aptam
abolish
abil
bind
fig
find
suggest
exposur
ggagg
grich
sequenc
rna
aptam
critic
interact
investig
effect
aptam
deubiquitin
activ
rna
aptam
transcrib
purifi
vitro
use
recombin
protein
vmeproteasom
hydrolysi
highli
sensit
fluorogen
substrat
dub
absenc
vmeproteasom
exhibit
littl
deubiquitin
activ
contrast
activ
presenc
vmeproteasom
exhibit
higher
hydrolysi
activ
vmeproteasom
alon
fig
addit
reaction
result
decreas
deubiquitin
activ
fig
supplementari
fig
inhibit
deubiquitin
activ
aptam
specif
aptam
fail
inhibit
dub
activ
fig
inhibit
deubiquitin
activ
dosedepend
manner
fig
supplementari
fig
catalyt
inact
mutant
exhibit
littl
deubiquitin
activ
unaffect
aptam
fig
f
indic
aptam
specif
inhibit
dub
activ
use
also
measur
enzym
kinet
recombin
vmeproteasom
presenc
absenc
aptam
supplementari
fig
k
bound
aptam
nm
significantli
higher
free
nm
howev
k
cat
valu
compar
regardless
whether
aptam
present
vs
control
rna
aptam
suggest
aptam
might
affect
substrat
bind
greater
extent
deubiquitin
activ
work
requir
determin
mechan
inhibit
aptam
result
strongli
indic
newli
identifi
aptam
effect
inhibit
deubiquitin
activ
vitro
test
whether
total
deubiquitin
activ
proteasom
affect
three
aptam
proteasom
treat
ubvm
show
signific
deubiquitin
activ
possibl
anoth
proteasom
dub
interact
fig
supplementari
fig
enzymat
redund
two
enzym
proteasom
unclear
consid
insignific
exhibit
much
weaker
ub
hydrolysi
activ
addit
aptam
strongli
inhibit
proteasomemedi
hydrolysi
fig
supplementari
fig
show
strongest
inhibitori
activ
test
proteasom
concentr
strong
inhibit
exhibit
could
result
abil
simultan
bind
data
shown
would
indic
play
signific
role
deubiquitin
polyubiquitin
substrat
previous
thought
studi
requir
determin
whether
chaintrim
suppress
proteasom
activ
effect
taken
togeth
result
provid
strong
evid
rna
aptam
block
activ
proteasom
dub
result
suggest
rna
aptam
bind
inhibit
deubiquitin
activ
previous
report
inhibit
ubchain
trim
effect
might
enhanc
proteolyt
activ
proteasom
vitro
vivo
explor
possibl
inhibitori
aptam
might
enhanc
proteasom
activ
use
sucllvyamc
fluorogen
report
substrat
proteasom
fluoresc
intens
result
sucllvyamc
hydrolysi
gradual
increas
time
fig
supplementari
fig
proteasom
activ
higher
rna
aptam
present
control
aptam
use
indic
inhibit
rna
aptam
result
facilit
proteasom
degrad
potenti
aptam
inhibit
prevent
dock
proteasom
howev
direct
pulldown
assay
indic
scenario
neg
fig
indic
inhibitori
effect
rna
aptam
mainli
dub
activ
also
use
physiolog
relev
polyubiquitin
protein
simultan
monitor
proteolysi
ub
chaintrim
cyclindepend
kinas
inhibitor
saccharomyc
cerevisia
polyubiquitin
use
cognat
enzym
respect
along
reconstitut
compon
ub
atp
result
gradual
degrad
purifi
proteasom
ad
addit
proteasom
inhibitor
mutant
protein
reaction
delay
degrad
fig
mix
purifi
proteasom
catalyt
inact
recombin
facilit
degrad
control
reaction
approxim
protein
degrad
proteasom
min
howev
presenc
aptam
almost
complet
degrad
condit
show
similar
kinet
proteasom
degrad
ad
reaction
scientif
report
doi
result
suggest
aptam
function
inhibit
catalyt
activ
repres
uniqu
biochem
therapeut
potenti
enhanc
proteasom
function
dysfunct
up
close
relat
tau
degrad
neurodegener
ad
tau
protein
thought
degrad
up
especi
earli
phase
tauopathi
ad
progress
human
ad
brain
proteasom
activ
impair
might
relat
agedepend
decreas
proteasom
activ
howev
could
also
consequ
accumul
tau
protein
verifi
proteasom
activ
aptam
facilit
tau
degrad
prepar
ubtau
abil
proteasom
degrad
ubtau
enhanc
presenc
aptam
fig
e
result
strongli
suggest
inhibit
rna
aptam
might
antagon
ub
chaintrim
proteasom
consequ
facilit
degrad
mani
up
substrat
investig
effect
aptam
hela
cell
viabil
small
molecul
inhibitor
exhibit
signific
cytotox
gml
aptam
exhibit
notic
cytotox
concentr
gml
fig
effect
aptam
proteasom
degrad
tau
examin
use
cell
line
express
longest
isoform
human
tau
upon
induct
doxycyclin
cell
express
dosedepend
manner
produc
sdsresist
tau
aggreg
day
cultur
aptam
transfect
cell
level
induc
tau
protein
significantli
decreas
dosedepend
manner
fig
turnov
tau
protein
facilit
aptam
shown
chx
chase
analysi
fig
condit
tau
mrna
level
compar
fig
indic
acceler
tau
degrad
occur
posttransl
aptam
reduc
cytotox
induc
oxid
stress
presenc
induc
tau
fig
treatment
proteasom
inhibitor
revers
protect
effect
aptam
result
indic
aptamerinduc
proteasom
activ
might
protect
cell
variou
stress
condit
includ
neurodegener
futur
work
necessari
determin
whether
rna
aptam
identifi
delay
format
tau
aggreg
mous
brain
identifi
three
rna
aptam
specif
bind
proteasomeassoci
dub
aptam
effect
inhibit
deubiquitin
activ
enhanc
proteasom
activ
vitro
cell
treat
aptam
show
facilit
degrad
solubl
tau
delay
accumul
tau
aggreg
enhanc
cellular
resist
proteotox
stress
fig
treatment
cell
aptam
yield
similar
result
suggest
activ
cellular
proteasom
possibl
inhibit
rna
aptam
advantag
small
molecul
therapeut
agent
find
suggest
aptam
could
use
treatment
diseas
associ
abnorm
proteasom
function
mammalian
proteasom
contain
three
distinct
dub
metalloproteas
constitu
compon
rp
cystein
proteas
revers
associ
respect
cognat
rp
thought
proteasom
regulatori
subunit
promot
substrat
degrad
dub
delay
degrad
cleav
base
polyub
chain
enabl
substrat
enter
cp
proteolysi
trim
ub
chain
distal
end
polyub
thu
decreas
affin
chain
ub
receptor
report
capabl
noncatalyt
inhibit
proteasom
although
molecular
mechan
respons
unclear
gener
ensur
short
nondegrad
ub
chain
substrat
releas
proteasom
small
molecul
inhibitor
identifi
highthroughput
screen
found
enhanc
proteasom
degrad
target
substrat
vitro
vivo
vitro
assay
use
ubtau
aptam
fig
indic
elev
proteasom
activ
might
due
catalyt
inhibit
ub
chaintrim
proteasom
substrat
effect
aptam
vitro
ub
degrad
promin
proteasom
satur
recombin
differ
respons
ubtau
aptam
suggest
chaintrim
may
univers
mechan
regul
rate
protein
turnov
weak
respons
tau
protein
inhibit
suggest
ub
chain
higher
bind
affin
proteasom
compar
aptam
enhanc
proteasom
degrad
howev
remain
determin
featur
ub
substrat
whether
geometr
morpholog
polyub
chain
affect
degrad
vivo
stabil
rna
aptam
improv
chemic
modif
biodistribut
clearanc
enhanc
conjug
chemic
moieti
polyethylen
glycol
cholesterol
aptam
first
report
earli
receiv
widespread
attent
potenti
therapeut
agent
aptam
shown
recogn
glioblastomaassoci
tenascinc
isoform
use
marker
diseas
activ
express
rna
aptam
ku
protein
breast
carcinoma
cell
potenti
sensit
anticanc
drug
etoposid
aptam
pegaptanib
slow
vision
loss
peopl
neovascular
agerel
macular
degener
approv
unit
state
food
drug
administr
incorpor
european
guidelin
sever
rna
dna
aptam
develop
use
preclin
clinic
trial
aptam
could
use
modul
proteotox
protein
cell
essenti
sequenc
structur
aptam
mediat
strong
interact
requir
elucid
would
assist
determin
aptam
truncat
modifi
without
advers
affect
bind
activ
vivo
enhanc
proteasom
activ
could
therapeut
strategi
treat
diseas
caus
accumul
damag
misfold
protein
neurodegen
diseas
cardiomyopathi
li
et
al
show
cellular
proteasom
level
increas
proteasom
upregul
cardiomyocyt
enhanc
proteasomemedi
remov
oxid
protein
protect
cell
cardiac
proteinopathi
myocardi
ischemia
current
studi
observ
inhibit
specif
aptam
appear
alter
proteasom
level
allevi
tauand
paraquatinduc
cytotox
result
indic
enhanc
proteasom
activ
benefici
effect
cell
viabil
condit
gener
proteotox
stress
remain
determin
whether
rna
aptam
modifi
form
acceler
degrad
proteopath
protein
previous
shown
abl
acceler
degrad
tau
ataxin
glial
fibrillari
acid
protein
applic
aptam
necessarili
limit
cytoprotect
role
toxic
protein
accumul
also
play
essenti
role
recycl
ub
monom
dynam
regul
ub
pool
cell
therefor
aptam
could
use
understand
molecular
mechan
activ
ub
homeostasi
cell
